Product Usage: This product is intended for research purposes only.
All product information available on this website is for educational purposes only. Any form of bodily introduction into humans or animals is strictly prohibited by law. This product should only be handled by licensed and qualified professionals. It is not a drug, food, or cosmetic, and must not be misbranded, misused, or mislabeled as such.
Ipamorelin 2mg
During our packaging transition, you may receive products with either our previous or updated label. Rest assured, the formulation, purity and quality remain exactly same as standards.
Ipamorelin is a synthetic pentapeptide and highly selective agonist of the growth hormone secretagogue receptor subtype 1a (GHS-R1a). The compound is characterized by strong receptor selectivity and a well-defined pharmacological profile, making it a useful tool for investigating GHS-R1a-mediated signal transduction and ligand-receptor interactions. Research applications include GHS-R1a pharmacology, receptor activation kinetics, signaling pathway characterization, structure-activity relationship investigations, and comparative analyses of growth hormone secretagogue receptor ligands.
- High Purity – 99% Purity Guaranteed
- Independently Lab Tested
- Research Grade Quality
- For Laboratory Research Use Only
3D Molecular Structure
Drag to rotate · scroll to zoom| Chemical Formula | C38H49N9O5 |
|---|---|
| Synonyms | 2-Methylalanyl-L-histidyl-3-(2-naphthyl)-D-alanyl-D-phenylalanyl-L-lysinamide, 170851-70-4, C38H49N9O5, CHEMBL58547, SCHEMBL183305, SCHEMBL8169698, MolPort-039-139-953, 5020AF, ZINC29562299, AKOS030573449, DB12370, NCGC00167295-01, FT-0696037 |
| Molar Mass | 711.9 g/mol |
| CAS Number | 170851-70-4 |
| PubChem CID | 9831659 |
| Total Compound Content | 2 mg per vial |
| Shelf Life | 36 months |
What makes Ipamorelin more selective than other GHS-R1a agonists?
Ipamorelin is characterized by a highly selective interaction with GHS-R1a and a well-defined pharmacological profile relative to earlier growth hormone secretagogue receptor ligands. This selectivity makes it a valuable research tool for investigating GHS-R1a-mediated signaling pathways, receptor activation kinetics, and ligand-receptor interactions without the broader receptor activity observed with less selective secretagogues.
What is the pharmacokinetic profile of Ipamorelin?
Pharmacokinetic investigations have reported a relatively short elimination profile compared with longer-acting GHS-R1a agonists. This characteristic makes Ipamorelin useful for studies examining receptor engagement dynamics, activation kinetics, signal transduction timing, and the temporal aspects of GHS-R1a-mediated signaling.
How does Ipamorelin compare with GHRH analogues in receptor pharmacology research?
Ipamorelin and GHRH analogues interact with distinct receptor systems and signaling pathways. Ipamorelin acts through GHS-R1a, whereas compounds such as CJC-1295 and Sermorelin target the growth hormone-releasing hormone receptor (GHRHR). Comparative investigations utilize these compounds to examine differences in receptor activation mechanisms, downstream signaling architecture, ligand selectivity, and pathway-specific signal transduction.
-
SALE
-
-
SALE
-
-
SALE
-
-
